Literature DB >> 10569966

Paediatric presentation of type 2 neurofibromatosis.

D G Evans1, J M Birch, R T Ramsden.   

Abstract

BACKGROUND: Neurofibromatosis type 2 (NF2) is a highly penetrant autosomal dominant condition predisposing affected individuals to schwannomas and meningiomas. The proportion of children presenting with meningioma or schwannoma who have NF2 is not well described, and neither is the mode of presentation in most children with the inherited disease. AIMS: To determine the frequency of childhood meningioma and schwannoma cases caused by NF2 and the mode of presentation.
METHODS: The records of the Manchester Children's Tumour Registry from 1954 were searched for cases of meningioma and schwannoma. Paediatric presentation in a large UK series of NF2 was also studied.
RESULTS: 18% (61/334) of patients with NF2 on the UK database presented in the paediatric age group (0-15 years), frequently with the symptoms of an isolated tumour. More than half had no family history to alert the clinician to their susceptibility. Three of 22 children presenting with a meningioma on the Manchester Children's Tumour Registry have gone on to develop classic features of NF2.
CONCLUSIONS: Clinicians should suspect NF2 in children presenting with meningioma, schwannoma, and skin features, such as neurofibromas/schwannomas, but fewer than 6 café au lait patches, who thus fall short of a diagnosis of neurofibromatosis type 1.

Entities:  

Mesh:

Year:  1999        PMID: 10569966      PMCID: PMC1718148          DOI: 10.1136/adc.81.6.496

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  20 in total

1.  A genetic study of type 2 neurofibromatosis in the United Kingdom. I. Prevalence, mutation rate, fitness, and confirmation of maternal transmission effect on severity.

Authors:  D G Evans; S M Huson; D Donnai; W Neary; V Blair; D Teare; V Newton; T Strachan; R Ramsden; R Harris
Journal:  J Med Genet       Date:  1992-12       Impact factor: 6.318

2.  Differential diagnosis of type 2 neurofibromatosis: molecular discrimination of NF2 and sporadic vestibular schwannomas.

Authors:  C L Wu; N Thakker; W Neary; G Black; R Lye; R T Ramsden; A P Read; D G Evans
Journal:  J Med Genet       Date:  1998-12       Impact factor: 6.318

3.  Von Recklinghausen neurofibromatosis. A clinical and population study in south-east Wales.

Authors:  S M Huson; P S Harper; D A Compston
Journal:  Brain       Date:  1988-12       Impact factor: 13.501

4.  Genetic linkage of von Recklinghausen neurofibromatosis to the nerve growth factor receptor gene.

Authors:  B R Seizinger; G A Rouleau; L J Ozelius; A H Lane; A G Faryniarz; M V Chao; S Huson; B R Korf; D M Parry; M A Pericak-Vance
Journal:  Cell       Date:  1987-06-05       Impact factor: 41.582

5.  A clinical study of type 1 neurofibromatosis in north west England.

Authors:  J M McGaughran; D I Harris; D Donnai; D Teare; R MacLeod; R Westerbeek; H Kingston; M Super; R Harris; D G Evans
Journal:  J Med Genet       Date:  1999-03       Impact factor: 6.318

6.  Preservation of hearing in neurofibromatosis 2.

Authors:  R T Miyamoto; R L Campbell; M Fritsch; G Lochmueller
Journal:  Otolaryngol Head Neck Surg       Date:  1990-10       Impact factor: 3.497

7.  Somatic mosaicism: a common cause of classic disease in tumor-prone syndromes? Lessons from type 2 neurofibromatosis.

Authors:  D G Evans; A J Wallace; C L Wu; L Trueman; R T Ramsden; T Strachan
Journal:  Am J Hum Genet       Date:  1998-09       Impact factor: 11.025

8.  Genetic linkage of bilateral acoustic neurofibromatosis to a DNA marker on chromosome 22.

Authors:  G A Rouleau; W Wertelecki; J L Haines; W J Hobbs; J A Trofatter; B R Seizinger; R L Martuza; D W Superneau; P M Conneally; J F Gusella
Journal:  Nature       Date:  1987 Sep 17-23       Impact factor: 49.962

9.  Genotype/phenotype correlations in type 2 neurofibromatosis (NF2): evidence for more severe disease associated with truncating mutations.

Authors:  D G Evans; L Trueman; A Wallace; S Collins; T Strachan
Journal:  J Med Genet       Date:  1998-06       Impact factor: 6.318

10.  Mosaicism in sporadic neurofibromatosis 2 patients.

Authors:  L Kluwe; V F Mautner
Journal:  Hum Mol Genet       Date:  1998-12       Impact factor: 6.150

View more
  33 in total

1.  Consensus recommendations for current treatments and accelerating clinical trials for patients with neurofibromatosis type 2.

Authors:  Jaishri O Blakeley; D Gareth Evans; John Adler; Derald Brackmann; Ruihong Chen; Rosalie E Ferner; C Oliver Hanemann; Gordon Harris; Susan M Huson; Abraham Jacob; Michel Kalamarides; Matthias A Karajannis; Bruce R Korf; Victor-Felix Mautner; Andrea I McClatchey; Harry Miao; Scott R Plotkin; William Slattery; Anat O Stemmer-Rachamimov; D Bradley Welling; Patrick Y Wen; Brigitte Widemann; Kim Hunter-Schaedle; Marco Giovannini
Journal:  Am J Med Genet A       Date:  2011-12-02       Impact factor: 2.802

Review 2.  Neurofibromatosis type 2.

Authors:  Ashok R Asthagiri; Dilys M Parry; John A Butman; H Jeffrey Kim; Ekaterini T Tsilou; Zhengping Zhuang; Russell R Lonser
Journal:  Lancet       Date:  2009-05-22       Impact factor: 79.321

3.  Association of Genetic Predisposition With Solitary Schwannoma or Meningioma in Children and Young Adults.

Authors:  Omar N Pathmanaban; Katherine V Sadler; Ian D Kamaly-Asl; Andrew T King; Scott A Rutherford; Charlotte Hammerbeck-Ward; Martin G McCabe; John-Paul Kilday; Christian Beetz; Nicola K Poplawski; D Gareth Evans; Miriam J Smith
Journal:  JAMA Neurol       Date:  2017-09-01       Impact factor: 18.302

Review 4.  Neurofibromatosis type 2.

Authors:  D G Evans; M Sainio; M E Baser
Journal:  J Med Genet       Date:  2000-12       Impact factor: 6.318

Review 5.  Pediatric meningioma: current approaches and future direction.

Authors:  Rishi S Kotecha; Reimar C Junckerstorff; Sharon Lee; Catherine H Cole; Nicholas G Gottardo
Journal:  J Neurooncol       Date:  2011-01-04       Impact factor: 4.130

6.  A patient with mosaic neurofibromatosis type 2 presenting with early onset meningioma.

Authors:  Yoyo Wing-Yiu Chu; Daniel Ka Leung Cheuk; Brian Hon Yin Chung; Naomi L Bowers; Shau-Yin Ha; Alan Kwok-Shing Chiang; Godfrey Chi-Fung Chan
Journal:  BMJ Case Rep       Date:  2014-11-18

7.  Pediatric neurofibromatosis type 2: clinical and molecular presentation, management of vestibular schwannomas, and hearing rehabilitation.

Authors:  Nicolas -Xavier Bonne; Rabih Aboukais; Marc Baroncini; Audrey Hochart; Pierre Leblond; Franck Broly; Frédérique Dubrulle; Jean-Paul Lejeune; Christophe Vincent
Journal:  Childs Nerv Syst       Date:  2016-10-04       Impact factor: 1.475

8.  Genotype-phenotype correlations for nervous system tumors in neurofibromatosis 2: a population-based study.

Authors:  Michael E Baser; Lisa Kuramoto; Harry Joe; J M Friedman; Andrew J Wallace; James E Gillespie; Richard T Ramsden; D Gareth R Evans
Journal:  Am J Hum Genet       Date:  2004-06-09       Impact factor: 11.025

Review 9.  Natural history of neurofibromatosis type 2 with onset before the age of 1 year.

Authors:  Martino Ruggieri; Anna Lia Gabriele; Agata Polizzi; Vincenzo Salpietro; Francesco Nicita; Piero Pavone; Nunzio Platania; Pietro Milone; Angela Distefano; Giuseppe Privitera; Giuseppe Belfiore; Francesca Granata; Rosario Caltabiano; Vincenzo Albanese; Lorenzo Pavone; Aldo Quattrone
Journal:  Neurogenetics       Date:  2013-02-03       Impact factor: 2.660

Review 10.  Neurofibromatosis type 2 (NF2): a clinical and molecular review.

Authors:  D Gareth R Evans
Journal:  Orphanet J Rare Dis       Date:  2009-06-19       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.